AIm: Surgery is a treatment option for medically intractable epilepsy patients. Abnormalities in regional cerebral glucose metabolism, as identified by 18-fluorodeoxyglucose positron emission tomography (FDG-PET) have predictive prognostic value in evaluating the outcome of epilepsy surgery. This study investigated the efficacy of FDG-PET for delineation of the epileptogenic zone (EZ) by comparing its consistency with other diagnostic tools and surgical outcome. mATErIAl and mEThOds: We analyzed the results of 121 consecutive patients evaluated for epilepsy surgery. FDG-PET results were crosschecked with magnetic resonance imaging (MRI) and electroencephalography (EEG) results, as well as postoperative outcome and pathology. rEsulTs: FDG-PET findings of 75 patients (62 %) were concordant with MRI (Mc-Nemar-χ2 test p=0.024, Kappa=0.22). Further, the PET findings were consistent with EEG, and was statistically significant, according to Post-hoc test, in temporal epilepsy (TLE) group (χ2=8.21 P=0.04). Both investigations revealed localizing information in 56 (46.2%) patients. Twenty-six (72.2%) MRI-negative patients had hypometabolism on PET. The pathology of the 10 PET-negative patients was 5 cases of mesial temporal sclerosis, 2 cortical dysplasia, 2 gliosis and one tumor. Seven (70%) of these patients' lesions originated from the temporal lobe. FDG-PET had correctly predicted the EZ in 37 (86%) of 43 patients who underwent surgery. CONClusION: FDG-PET results may not be strongly associated with EZ but represent an additional tool in delineation of EZ during the noninvasive phase of presurgical evaluation. KEywOrds: Intractable epilepsy, Positron emission tomography, Surgery, Prognosis ÖZ AmAÇ: Epilepsi cerrahisi, medikal tedaviye dirençli epilepsi hastalarında bir tedavi seçeneğidir. Dirençli epilepside 18-floro-deoksiglukoz pozitron emisyon tomografisiyle (FDG-PET) serebral glukoz metabolizma anomalilerinin, cerrahi prognozun öngörülmesinde belirleyici değeri mevcuttur. Çalışmada, FDG-PET sonuçlarının diğer tanısal araçlar ve cerrahi sonuçlarının karşılaştırılmasıyla epileptojenik alan (EA)'ın sınırlarının belirlenmesindeki etkinliğini araştırılmıştır. yÖNTEm ve GErEÇlEr: Çalışmada, epilepsi cerrahisi amaçlı incelenen 121 hastanın FDG-PET, manyetik rezonans görüntüleme (MRI) ve elektroensefalografi (EEG) sonuçları değerlendirilmiştir. FDG-PET sonuçları MRI ve EEG sonuçlarıyla uyumluluğuna bakılmış, postoperatif cerrahi sonuçları ve patolojiyle karşılaştırılmıştır. FDG-PET görüntüleri, bölgesel hipometabolik alanlar değerlendirilerek, genişliğe bakılmadan incelenmiştir. BulGulAr: 75 hastanın (%62) FDG-PET sonuçları MRI sonuçlarıyla uyumlu olarak tespit edildi. 024; Kappa=0,22) Özellikle temporal lob epilepsi (TLE) grubunda PET, EEG post-hoc test sonuçlarına göre (χ2=8,21 P=0,04) istatistiksel anlamlı düzeyde uyumluydu. 56 hastada (%46,2) her iki tetkik epileptojenik alanı lokalize edebildi. 26 MRI-negatif hastanın (%72,2) PET görüntülemelerinde hipometabolizma mevcuttu. PET-negatif 10 hastanın patoloji...

No abstract

Lafora disease is a rare, fatal, autosomal recessive progressive myoclonic epilepsy. The condition is characterised by seizures, myoclonus and dementia. In this case report, a patient who presented with generalised tonic‐clonic seizures at the age of 30 is discussed. Until the age of 48, the patient did not have myoclonic jerks or ataxia clinically, but had well controlled seizures. He developed dementia and late extrapyramidal signs. Axillary skin biopsy revealed typical Lafora inclusion bodies. Genetic analysis showed a mutation in the EMP2B gene. To our knowledge, this is the first description of a patient suffering from a Lafora disease without disabling myoclonus and ataxia but rather rare seizures, extrapyramidal signs, and dementia.

Protective neutralizing antibody titers reduce in time after COVID-19 vaccinations, as in individuals who have had COVID-19. This study aimed to evaluate the safety and immunogenicity of CoronaVac and TURKOVAC vaccines used as a booster dose after CoronaVac primary vaccination. This double-blind, randomized, controlled, phase II, multicenter study included healthy male and female adults (18–60 years) who were vaccinated with two doses of CoronaVac vaccine and did not exceed the duration of at least 90 days and a maximum of 270 days from the second dose of vaccination. Among 236 eligible volunteers, 222 were recruited for randomization between July 12, 2021 and September 10, 2021; 108 and 114 were randomized to the TURKOVAC and CoronaVac arms, respectively. The primary endpoint was adverse events (AEs) (ClinicalTrials.gov; Identifier: NCT04979949). On day 28, at the neutralizing antibody threshold of 1/6, the positivity rate reached 100% from 46.2% to 98.2% from 52.6% in the TURKOVAC and CoronaVac arms, respectively, against the Wuhan variant and the positivity rate reached 80.6% from 8.7% in the TURKOVAC arm vs. 71.9% from 14.0% in the CoronaVac arm against the Delta variant. IgG spike antibody positivity rate increased from 57.3% to 98.1% and from 57.9% to 97.4% in the TURKOVAC and CoronaVac arms, respectively. The TURKOVAC and CoronaVac arms were comparable regarding the frequency of overall AEs. Both vaccines administered as booster yielded higher antibody titers with acceptable safety profiles.